1-3 of 3
Lloyd Haskell
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Healthcare Cost Impact of Continued Anticoagulation Therapy with Rivaroxaban Versus Aspirin for Prevention of Recurrent Symptomatic Venous Thromboembolism in the Einstein Choice Trial Population

Bruce L. Davidson, MD MPH, Philip S. Wells, MD FRCPC, MSc, Martin H. Prins, MD PhD, Jan Beyer-Westendorf, MD, Anthonie WA. Lensing, MD PhD, Lloyd Haskell, MD, Bennett Levitan, MD PhD, François Laliberté, Veronica Ashton, MPH, Yongling Xiao, PhD, Dominique Lejeune, Concetta Crivera, Patrick Lefebvre, MA, Qi Zhao, MPH, Zhong Yuan, MD PhD, Jeff Schein, Paolo Prandoni, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 218.
https://doi.org/10.1182/blood.V130.Suppl_1.218.218
Published: 2017
Journal Articles

The MAGELLAN Study: An Analysis of Outcomes Utilizing D-Dimer

Alexander T Cohen, Theodore E Spiro, Paul Burton, Harry R Büller, Lloyd Haskell, Da-Yi Hu, Russell D Hull, Alexandre Mebazaa, Geno J Merli, Sebastian Schellong, Alex C Spyropoulos, Victor F Tapson
Journal: Blood
Blood (2011) 118 (21): 542.
https://doi.org/10.1182/blood.V118.21.542.542
Published: 2011
Journal Articles

Rivaroxaban Compared with Enoxaparin for the Prevention of Venous Thromboembolism In Acutely Ill Medical Patients: MAGELLAN Study Methodology

Alexander Thomas Cohen, Theodore Erich Spiro, Harry Roger Büller, Lloyd Haskell, Da-Yi Hu, Russell Hull, Alexandre Mebazaa, Geno Merli, Sebastian Schellong, Alexander Spyropoulos, Victor Tapson
Journal: Blood
Blood (2010) 116 (21): 3331.
https://doi.org/10.1182/blood.V116.21.3331.3331
Published: 2010